| Making the first move in EGFR-driven or ALK-driven NSCLC: first-generation or next-generation TKI? G Recondo, F Facchinetti, KA Olaussen, B Besse, L Friboulet Nature reviews Clinical oncology 15 (11), 694-708, 2018 | 303 | 2018 |
| BRAF in non-small cell lung cancer (NSCLC): pickaxing another brick in the wall A Leonetti, F Facchinetti, G Rossi, R Minari, A Conti, L Friboulet, M Tiseo, ... Cancer treatment reviews 66, 82-94, 2018 | 159 | 2018 |
| Crizotinib-Resistant ROS1 Mutations Reveal a Predictive Kinase Inhibitor Sensitivity Model for ROS1- and ALK-Rearranged Lung Cancers F Facchinetti, Y Loriot, MS Kuo, L Mahjoubi, L Lacroix, D Planchard, ... Clinical Cancer Research 22 (24), 5983-5991, 2016 | 144 | 2016 |
| Diverse resistance mechanisms to the third-generation ALK inhibitor lorlatinib in ALK-rearranged lung cancer G Recondo, L Mezquita, F Facchinetti, D Planchard, A Gazzah, L Bigot, ... Clinical Cancer Research 26 (1), 242-255, 2020 | 142 | 2020 |
| Molecular mechanisms of acquired resistance to third-generation EGFR-TKIs in EGFR T790M-mutant lung cancer C Ricordel, L Friboulet, F Facchinetti, JC Soria Annals of Oncology 29, i28-i37, 2018 | 123 | 2018 |
| Chemotherapy in metastatic renal cell carcinoma today? A systematic review S Buti, M Bersanelli, A Sikokis, F Maines, F Facchinetti, E Bria, A Ardizzoni, ... Anti-cancer drugs 24 (6), 535-554, 2013 | 117 | 2013 |
| First-line pembrolizumab in advanced non–small cell lung cancer patients with poor performance status F Facchinetti, G Mazzaschi, F Barbieri, F Passiglia, F Mazzoni, R Berardi, ... European Journal of Cancer 130, 155-167, 2020 | 111 | 2020 |
| Facts and new hopes on selective FGFR inhibitors in solid tumors F Facchinetti, A Hollebecque, R Bahleda, Y Loriot, KA Olaussen, ... Clinical Cancer Research 26 (4), 764-774, 2020 | 109 | 2020 |
| The circulating pool of functionally competent NK and CD8+ cells predicts the outcome of anti-PD1 treatment in advanced NSCLC G Mazzaschi, F Facchinetti, G Missale, D Canetti, D Madeddu, A Zecca, ... Lung cancer 127, 153-163, 2019 | 104 | 2019 |
| Targeting the MET gene for the treatment of non-small-cell lung cancer F Gelsomino, F Facchinetti, ER Haspinger, MC Garassino, L Trusolino, ... Critical reviews in oncology/hematology 89 (2), 284-299, 2014 | 103 | 2014 |
| Primary resistance to osimertinib due to SCLC transformation: Issue of T790M determination on liquid re-biopsy R Minari, P Bordi, M Del Re, F Facchinetti, F Mazzoni, F Barbieri, ... Lung Cancer 115, 21-27, 2018 | 92 | 2018 |
| A prospective examination of circulating tumor cell profiles in non-small-cell lung cancer molecular subgroups CR Lindsay, V Faugeroux, S Michiels, E Pailler, F Facchinetti, D Ou, ... Annals of Oncology 28 (7), 1523-1531, 2017 | 88 | 2017 |
| Notch pathway in small-cell lung cancer: from preclinical evidence to therapeutic challenges A Leonetti, F Facchinetti, R Minari, A Cortellini, CD Rolfo, E Giovannetti, ... Cellular oncology 42, 261-273, 2019 | 73 | 2019 |
| Oncogene addiction in non-small cell lung cancer: focus on ROS1 inhibition F Facchinetti, G Rossi, E Bria, JC Soria, B Besse, R Minari, L Friboulet, ... Cancer Treatment Reviews 55, 83-95, 2017 | 68 | 2017 |
| Molecular mechanisms of resistance to BRAF and MEK inhibitors in BRAFV600E non–small cell lung cancer F Facchinetti, L Lacroix, L Mezquita, JY Scoazec, Y Loriot, L Tselikas, ... European Journal of Cancer 132, 211-223, 2020 | 67 | 2020 |
| ROS1-rearranged non–small-cell lung cancer is associated with a high rate of venous thromboembolism: analysis from a phase II, prospective, multicenter, two-arms trial (METROS) R Chiari, B Ricciuti, L Landi, AM Morelli, A Delmonte, G Spitaleri, ... Clinical Lung Cancer 21 (1), 15-20, 2020 | 63 | 2020 |
| New pathways in immune stimulation: targeting OX40 CAC Silva, F Facchinetti, B Routy, L Derosa ESMO open 5 (1), e000573, 2020 | 62 | 2020 |
| Detection of ROS1 rearrangement in non-small cell lung cancer: current and future perspectives G Rossi, G Jocollé, A Conti, M Tiseo, F Zito Marino, G Donati, R Franco, ... Lung Cancer: Targets and Therapy, 45-55, 2017 | 62 | 2017 |
| Adding PD-1/PD-L1 inhibitors to chemotherapy for the first-line treatment of extensive stage small cell lung cancer (SCLC): a meta-analysis of randomized trials F Facchinetti, M Di Maio, M Tiseo Cancers 12 (9), 2645, 2020 | 54 | 2020 |
| Lung toxicity in non–small-cell lung cancer patients exposed to ALK inhibitors: report of a peculiar case and systematic review of the literature B Pellegrino, F Facchinetti, P Bordi, M Silva, L Gnetti, M Tiseo Clinical Lung Cancer 19 (2), e151-e161, 2018 | 54 | 2018 |
